Longevity.Technology (@LongevityTech)· LongevityTech·· 5 天前评分8
HepaRegeniX药物在肝切除患者中达标
HepaRegeniX’s darizmetinib clears milestone in major liver resection patients, with favorable safety profile and Phase 2a advance lined up.
导读
HepaRegeniX的darizmetinib在大型肝切除患者中通过里程碑，安全性良好，Phase 2a即将推进。 https://vist.ly/5mpht #longevity #geroscience #HepaRegeniX #darizmetinib #Phase2a
来源：Longevity.Technology (@LongevityTech) · x.com